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Abstract
Introduction: Integration of services to screen and manage mental health and substance use disorders (MSDs) into HIV care
settings has been identified as a promising strategy to improve mental health and HIV treatment outcomes among people liv-
ing with HIV/AIDS (PLWHA) in low- and middle-income countries (LMICs). Data on the extent to which HIV treatment sites in
LMICs screen and manage MSDs are limited. The objective of this study was to assess practices for screening and treatment
of MSDs at HIV clinics in LMICs participating in the International epidemiology Databases to Evaluate AIDS (IeDEA)
consortium.
Methods: We surveyed a stratified random sample of 95 HIV clinics in 29 LMICs in the Caribbean, Central and South Amer-
ica, Asia-Pacific and sub-Saharan Africa. The survey captured information onsite characteristics and screening and treatment
practices for depression, post-traumatic stress disorder (PTSD), substance use disorders (SUDs) and other mental health
disorders.
Results: Most sites (n = 76, 80%) were in urban areas. Mental health screening varied by disorder: 57% of sites surveyed
screened for depression, 19% for PTSD, 55% for SUDs and 29% for other mental health disorders. Depression, PTSD, SUDs
and other mental health disorders were reported as managed on site (having services provided at the HIV clinic or same
health facility) at 70%, 51%, 41% and 47% of sites respectively. Combined availability of screening and on-site management of
depression, PTSD, and SUDs, and other mental health disorders was reported by 42%, 14%, 26% and 19% of sites, respec-
tively. On-site management of depression and PTSD was reported significantly less often in rural as compared to urban set-
tings (depression: 33% and 78% respectively; PTSD: 24% and 58% respectively). Screening for depression and SUDs was least
commonly reported by HIV programmes that treated only children as compared to HIV programmes that treated only adults
or treated both adults and children.
Conclusions: Significant gaps exist in the management of MSDs in HIV care settings in LMICs, particularly in rural settings.
Identification and evaluation of optimal implementation strategies to scale and sustain integrated MSDs and HIV care is
needed.
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1 | INTRODUCTION
Mental health and substance use disorders (MSDs) are highly
prevalent among persons living with HIV/AIDS (PLWHA) glob-
ally, including in low- and middle-income countries (LMICs)
and more prevalent among PLWHA compared to the general
population [1,2]. According to the Diagnostic and Statistical
Manual of Mental Disorders, Fifth Edition (DSM-5), mental
disorders are “characterized by clinically significant distur-
bance in an individual’s cognition, emotion regulation, or beha-
viour that reflects a dysfunction in the psychological,
biological, or developmental processes underlying mental func-
tioning”[3]. Common mental disorders include depression and
post-traumatic stress disorder (PTSD). As defined by the
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DSM-5, substance use disorders (SUDs) involve a “cluster of
cognitive, behavioural and psychological symptoms indicating
that the individual continues using the substance despite sig-
nificant substance-related problems” [3]. SUDs include alcohol
and drug use disorders. Approximately 50% of PLWHA in
LMICs meet diagnostic criteria for one or more MSDs [1,2].
Poor mental health has been associated with suboptimal
HIV treatment outcomes throughout the HIV care cascade,
including late initiation of combination antiretroviral therapy
(ART), poor ART adherence and lack of viral suppression [4-7].
MSDs remain under-diagnosed and under-treated in many
LMICs. Because MSDs are common and drive suboptimal out-
comes throughout the HIV care cascade, untreated MSDs
may serve as significant, but modifiable barriers to optimal
HIV treatment.
Evidence-based management for many MSDs significantly
improves mental health outcomes [8-11]. Integration of evi-
dence-based interventions to manage MSDs into HIV care has
been identified as a promising strategy to improve mental
health and HIV treatment outcomes of PLWHA in LMICs
[12,13]. The World Health Organization (WHO) recommends
integration of or linkage to mental health services for PLWHA,
where possible, and has developed the Mental Health Gap
Action Programme (mhGAP) to provide evidence-based guide-
lines for the diagnosis and management of priority mental
health disorders in routine healthcare settings [14,15]. The
extent to which screening and management of MSDs is inte-
grated into HIV treatment programmes in LMICs remains lar-
gely unknown [1,16]. The objective of this study was to
describe MSD screening and management practices in a rep-
resentative sample of HIV treatment sites in LMICs participat-
ing in the International epidemiology Databases to Evaluate
AIDS (IeDEA) consortium.
2 | METHODS
The IeDEA consortium (iedea.org) is a global research consor-
tium including HIV care and treatment programmes from
North America, the Caribbean, Central and South America,
Asia-Pacific and sub-Saharan Africa [17-19]. IeDEA is funded
by the U.S. National Institutes of Health to provide a resource
for globally diverse clinical HIV/AIDS observational data
[18,19]. Our survey was conducted with a stratified random
sample of 95 HIV treatment sites in 29 LMICs in the Carib-
bean, Latin America, the Asia-Pacific region and sub-Saharan
Africa (See Figure 1). To participate in IeDEA, HIV care and
treatment sites must be located in one of the countries in
which IeDEA is currently operating and have the capacity to
routinely contribute electronic data to the IeDEA consortium.
In this way, IeDEA sites may have more resources and be
more highly functioning than sites in that country that are not
participating in IeDEA. Based on previous IeDEA sites assess-
ments, IeDEA sites represent various levels of the health sys-
tem, are privately and publicly funded, and are located in
urban and rural areas [20,21].
2.1 | Survey development
IeDEA investigators, in collaboration with the President’s
Emergency Plan for AIDS Relief Non-Communicable Diseases
(PEPFAR NCD) working group, developed a survey to assess
integration of screening and treatment practices for numerous
non-communicable diseases (NCDs) into HIV care, including
MSDs. The current analysis is limited to assessment of the
integration of screening and management practices for MSDs.
2.2 | Sampling frame
This study surveyed a stratified random sample of HIV treat-
ment programmes across the six low- and middle-income
IeDEA regions: the Caribbean, Central and South America,
Asia-Pacific, Central Africa, East Africa, Southern Africa and
West Africa. When possible, the sampling frame was stratified
according to the following site characteristics: setting (i.e.
urban, rural), patient population (i.e. adults only, children/ado-
lescents only, adults and children/adolescents), and level of
care (i.e. health centre; district hospital; regional, provincial, or
university hospital) at the country level. However, stratification
by the three stratification variables was not possible for all
countries (e.g. all IeDEA sites in Co^te d’Ivoire are urban).
Stratification variables were obtained from the most recent
site assessment [21] and verified during implementation of
the current survey. A random sampling strategy was used so
that sites selected would be representative of clinics located
in LMICs within IeDEA. Eligible sites were: (1) HIV treatment
programmes; (2) current members of the IeDEA consortium;
and (3) located in one of the six low- and middle-income
IeDEA regions.
2.3 | Data collection and statistical analyses
Data collection occurred between August 2016 and May
2017. English and French versions of the survey were avail-
able online and as paper-based instruments. The online ver-
sion was implemented using REDCap (projectredcap.org), a
secure web-based application hosted by the University of
Bern [22]. IeDEA research coordinators distributed surveys to
sites in their region. Survey instructions explained that the
survey should be completed by individual(s) knowledgeable
about clinic capacity and services offered and encouraged the
respondent to contact other people at the site if they did not
know or were uncertain about answers to survey questions.
Surveys completed on paper were entered into REDCap by
regional representatives or study staff members. The survey
captured information onsite characteristics (level of care, set-
ting, patient population, sector) and screening and manage-
ment practices for depression, PTSD, SUDs, including alcohol
and drug use disorders, and other serious mental illnesses,
including schizophrenia and bipolar disorder. Respondents
were asked separately about screening and management pro-
cedures for: depression, PTSD, SUDs and other serious men-
tal illnesses. The survey was translated into French and
sections were back-translated into English. For each MSD
assessed, respondents were asked if their HIV treatment site:
screened patients, had a written protocol for screening, how
they screened, whom they screened, had a written protocol
for management, where management was provided, and the
type of staff members responsible for management. Sites and
coordinating centres for all IeDEA regions had Institutional
Review Board approvals that permitted collection of site-level
data for this survey. This survey collected only site-level data.
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Descriptive statistics summarize the prevalence of screen-
ing and management of MSDs overall and by World Bank
Income designation of the country in which the site was
located. Analyses between site-level characteristics and
screening and treatment of MSDs were conducted using chi-
squared or Fisher’s exact tests. Results were presented over-
all and by World Bank Income Designation (as of July 2015)
of the country in which each site was located.
3 | RESULTS
Of the initial 162 sites approached for participation, 86 sites
completed the survey. The main reason for non-participation
was that sites were no longer participating in IeDEA (n = 43;
56%). This attrition occurred over two to three years and
represents a challenge of conducting longitudinal research in
real-world service settings. Other reasons for non-participa-
tion included: sites had temporarily suspended operations or
were undergoing structural changes (n = 14; 18%), sites had
closed down (n = 6; 8%), non-response (n = 2; 3%), or other
reasons (n = 11; 15%). Nine replacement sites were selected
and participated resulting in a final sample of 95 sites.
Replacement sites were randomly selected from those remain-
ing in that stratum. If no other sites remained in that stratum,
no replacement site was chosen. Approximately 43% of
respondents described themselves as principal investigators,
26% as head clinician, clinical manager, or nurse, 9% as site
manager and 23% as performing another role at the site.
3.1 | Site characteristics
Among the participating sites, 59 were located in sub-Saharan
Africa, 28 in the Asia-Pacific region and 8 in the Caribbean
Figure 1. Geographic distribution of the 95 HIV treatment sites from the IeDEA network participating in the MSD survey.
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Table 1. Screening of mental and substance use disorders in 95 HIV treatment programmes within the IeDEA consortium, overall
and by World Bank Income designation
All n = 95
n (%)
Low-income countries
n = 25 n (%)
Lower middle-income
countries n = 42 n (%)
Upper middle income-
countries n = 28 n (%)
Depression
Depression screening 54 (57) 18 (72) 24 (57) 12 (43)
Written guidelines in place 20 (21) 9 (36) 7 (17) 4 (14)
Patient population screened
All patients 16 (17) 5 (20) 7 (17) 4 (14)
Symptomatic patients 36 (38) 13 (52) 15 (36) 8 (29)
Other 1 (1) 0 1 (2) 0
Timing of screeninga
Enrolment into care 16 (17) 7 (28) 5 (12) 4 (14)
ART initiation 6 (6) 4 (16) 2 (5) 0
Annually 2 (2) 0 1 (2) 1 (4)
Every visit 27 (28) 14 (56) 10 (24) 3 (11)
Other 20 (21) 3 (12) 11 (26) 6 (21)
Post-traumatic stress disorder (PTSD)
PTSD screening 18 (19) 10 (40) 5 (12) 3 (11)
Written guidelines in place 10 (11) 7 (28) 2 (5) 1 (4)
Patient population screened
All patients 3 (3) 3 (12) 0 0
Patients with symptoms 14 (15) 7 (28) 4 (9) 3 (11)
Other 0 0 0 0
Timing of screeninga
Enrolment into care 6 (6) 4 (16) 2 (5) 0
ART initiation 0 0 0 0
Annually 0 0 0 0
Every visit 13 (14) 8 (32) 3 (7) 2 (7)
Other 4 (4) 2 (8) 1 (2) 1 (4)
Substance use disorders
Substance use disorders screening 52 (55) 12 (48) 27 (64) 13 (46)
Written guidelines in place 19 (20) 6 (24) 7 (17) 6 (21)
Patient population screened
All patients 29 (31) 5 (20) 17 (40) 7 (25)
Patients with symptoms 19 (20) 7 (28) 8 (19) 4 (14)
Other 4 (4) 0 2 (5) 2 (7)
Timing of screeninga
Enrolment into care 28 (29) 4 (16) 16 (38) 8 (29)
ART initiation 6 (6) 2 (8) 3 (7) 1 (4)
Annually 1 (1) 0 0 1 (4)
Every visit 27 (28) 11 (44) 11 (26) 5 (18)
Other 8 (8) 1 (4) 5 (12) 2 (7)
Other mental health disorders
Other mental health disorders screening 28 (29) 12 (48) 10 (24) 6 (21)
Written guidelines in place 11 (12) 6 (24) 3 (7) 2 (7)
Patient population screened
All patients 6 (6) 3 (12) 2 (5) 1 (4)
Patients with symptoms 21 (22) 9 (36) 7 (17) 5 (18)
Other 1 (1) 0 1 (2) 0
Timing of screeninga
Enrolment into care 7 (7) 3 (12) 2 (5) 2 (7)
ART initiation 4 (4) 2 (8) 2 (5) 0
Annually 0 0 0 0
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and Latin America. The geographical distribution of the 95
participating sites is provided in Figure 1. The majority of sites
treated adults and children/adolescents (64%) and were
located in urban settings (80%).
3.1.1 | Availability of staff members with mental
health training
Twenty-three percent of participating sites reported having
staff members trained in psychiatry or psychology at the HIV
treatment site. Forty-two percent reported having such staff
members available at their health facility, but not at the HIV
treatment site. Among sites that reported having staff mem-
bers trained in psychiatry or psychology at the HIV treatment
site (n = 22), 50% reported that such staff members were
physicians, 36% reported that they were mid-level providers,
32% reported that they were nurses or nursing assistants,
27% reported that they were other types of clinical staff
members, and 5% reported that they were non-clinical staff
members.
3.2 | Screening of MSDs
Fifty-seven percent of participating sites reported screening
HIV patients for depression (Table 1). Twenty-one percent of
sites reported having written guidelines for depression
screening. More than one-third (38%) reported targeted
screening of only symptomatic patients while 17% reported
screening all patients for depression. Twenty-eight percent of
sites reported screening patients for depression at every visit,
17% at enrolment into care, 6% at ART initiation and 2%
reported annual depression screening. Screening for depres-
sion was most commonly reported in low-income countries
(72%).
Screening for PTSD was reported by 19% of participating
sites. Eleven percent of sites reported having guidelines for
PTSD screening. Fifteen percent of sites reported targeted
PTSD screening of only symptomatic patients and 3%
reported screening all patients for PTSD. Fourteen percent of
sites reported screening patients for PTSD at every visit and
6% reported screening patients for PTSD at enrolment into
care. Similar to depression, PTSD screening was most com-
monly reported in low-income countries (40%).
Half (55%) of sites reported screening for SUDs, including
alcohol and drug use disorders. Twenty percent of sites
reported having guidelines for SUDs screening. Thirty-one
percent of sites reported screening all patients for SUDs and
20% reported targeted screening of only symptomatic
patients. Approximately one-quarter (28%) of sites reported
screening for SUDs at every visit while 29% reported
screening for SUDs at enrolment into care. SUDs screening
was most commonly reported in lower middle-income coun-
tries (64%).
Twenty-nine percent of participating sites reported screening
patients for other mental health disorders, such as schizophre-
nia or bipolar disorder. Twelve percent reported that they had
written guidelines for screening for other mental health disor-
ders. Twenty-two percent of clinics reported targeted screening
of symptomatic patients for other mental health disorders while
6% reported screening all patients for other mental health dis-
orders. Seventeen percent of clinics reported that they
screened for other mental health disorders at every visit.
3.3 | Management of MSDs
Depression was reported to be managed on site (defined as
providing services at the HIV clinic or the same health facility)
in 70% of sites (See Table 2). Services to manage depression
were reported to be available only off site in 18% of sites and
were reported to be unavailable (either on site or off site) in
12% of sites. Individual counselling or group therapy to man-
age depression was reported to be available on site at 70%
and 49% of sites respectively. On-site management of depres-
sion was most commonly reported in upper middle-income
countries (89%) and least commonly reported in lower mid-
dle-income countries (51%).
PTSD was reported to be managed on site in 51% of partic-
ipating sites. One-third of sites reported that services to man-
age PTSD were only available off site, and 16% reported that
such services were not available. Individual counselling or psy-
chotherapy to manage PTSD was reported to be available on
site at 54% of participating clinics and support groups or
group therapy to manage PTSD was reported to be available
on site at 43% of participating sites. On-site management of
PTSD was most commonly reported in upper middle-income
countries (85%) and least commonly reported in lower mid-
dle-income countries (23%).
Services to manage SUDs were reported to be available on
site at 41% of clinics, only off site at 46% of sites, and were
reported to be unavailable at 13% of sites. Services to manage
SUDs were more commonly reported in upper middle-income
countries (61%) than in low-income countries (39%) or lower
middle-income countries (29%).
Services to manage other mental health disorders (e.g.
schizophrenia, bipolar disorder) were available on site at 47%
of participating sites, were reported to be available only off site
in 36% of sites, and were reported to be unavailable at 16% of
sites. Selective serotonin reuptake inhibitors (SSRIs), benzodi-
azepines and other psychiatric medications were reportedly
available on site at 52%, 81% and 71% of sites respectively.
Table 1. (Continued)
All n = 95
n (%)
Low-income countries
n = 25 n (%)
Lower middle-income
countries n = 42 n (%)
Upper middle income-
countries n = 28 n (%)
Every visit 16 (17) 10 (40) 4 (9) 2 (7)
Other 9 (9) 2 (8) 5 (12) 2 (7)
a
Categories are not mutually exclusive.
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Table 2. Management of mental and substance use disorders at 95 HIV treatment programmes within the IeDEA consortium,
overall and by World Bank Income designation
All
n = 95
n (%)
Low-income countries
n = 25
n (%)
Lower middle income-countries
n = 42
n (%)
Upper middle income-countries
n = 28
n (%)
Depression
Management of depressiona
Available on site 64 (70) 18 (78) 21 (51) 25 (89)
Available only off site 17 (18) 3 (13) 12 (29) 2 (7)
Not available 11 (12) 2 (9) 8 (20) 1 (4)
Missing 3 2 1 0
Individual counselling or psychotherapya
Available on site 66 (70) 20 (83) 21 (50) 25 (89)
Available only off site 15 (16) 1 (4) 11 (26) 3 (11)
Not available 13 (14) 3 (13) 10 (24) 0
Missing 1 1 0 0
Support group or group therapya
Available on site 46 (49) 16 (67) 12 (28) 18 (64)
Available only off site 19 (20) 1 (4) 13 (31) 5 (18)
Not available 29 (31) 7 (29) 17 (40) 5 (18)
Missing 1 1 0 0
PTSD
Management of PTSDa
Available on site 45 (51) 14 (61) 9 (23) 22 (85)
Available only off site 29 (33) 6 (26) 19 (49) 4 (15)
Not available 14 (16) 3 (13) 11 (28) 0
Missing 7 2 3 2
Individual counselling or psychotherapya
Available on site 51 (54) 16 (67) 15 (36) 20 (71)
Available only off site 20 (21) 3 (13) 12 (29) 5 (18)
Not available 23 (24) 5 (21) 15 (36) 3 (11)
Missing 1 1 0 0
Support group or group therapya
Available on site 40 (43) 14 (58) 12 (29) 14 (50)
Available only off site 20 (21) 3 (13) 11 (27) 6 (21)
Not available 33 (35) 7 (29) 18 (44) 8 (29)
Missing 2 1 1 0
Substance use disorders
Management of substance use disordersa
Available on site 38 (41) 9 (39) 12 (29) 17 (61)
Available only off site 42 (46) 10 (43) 21 (51) 11 (39)
Not available 12 (13) 4 (17) 8 (20) 0
Missing 3 2 1 0
Other mental health disorders
Management of other mental health disordersa
Available on site 43 (47) 12 (50) 10 (24) 21 (81)
Available only off site 33 (36) 8 (33) 20 (49) 5 (19)
Not available 15 (16) 4 (17) 11 (27) 0
Missing 4 1 1 2
Written guidelines in place 14 (15) 7 (28) 3 (7) 4 (14)
Parcesepe AM et al. Journal of the International AIDS Society 2018, 21:e25101
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25101/full | https://doi.org/10.1002/jia2.25101
6
On-site management of all MSDs assessed was significantly
more commonly reported among sites that reported having
staff members with mental health training. Ninety percent of
sites that reported having staff members on site with mental
health training reported on-site management of depression
compared to 33% of sites that reported not having staff
members on site with mental health training (data not shown).
Similarly, 73% of sites that reported having staff members on
site with mental health training reported on-site management
of PTSD compared to 16% of sites that reported not having
staff members on site with mental health training.
3.4 | Combined availability of screening and on-site
management of MSDs
Almost half of sites (42%) reported screening and on-site man-
agement of depression (Table 3). In contrast, 14% reported
only screening for depression, while 27% of sites reported
only on-site management for depression. Fourteen percent of
sites reported both screening and on-site management of
PTSD. Seven percent reported screening, but not on-site man-
agement for PTSD, while 38% of sites reported on-site man-
agement, but not screening for PTSD. One-quarter (26%)
reported screening and on-site management of SUDs. Thirty
percent of sites reported screening, but not on-site manage-
ment of SUDs, while 15% of sites reported on-site manage-
ment, but not screening for SUDs. Nineteen percent of sites
reported both screening and on-site management of other
mental health disorders while 41% reported neither screening
nor on-site management of other mental health disorders.
3.5 | Site characteristics and screening and
management of MSDs
Screening of PTSD was significantly less commonly reported
in urban compared to rural settings (Table 4). Screening for
depression and SUDs was less commonly reported by paedi-
atric only sites than adult sites or sites that treat adults and
children/adolescents. On-site management of depression,
PTSD, SUDs and other mental health disorders was associ-
ated with level of care of the health facility and patient popu-
lation treated. On-site management of depression, PTSD, and
other mental health disorders was most commonly reported
by regional, provincial or universities hospitals and least com-
monly reported by health centres. On-site management of
SUDs was most commonly reported by district hospitals and
Table 2. (Continued)
All
n = 95
n (%)
Low-income countries
n = 25
n (%)
Lower middle income-countries
n = 42
n (%)
Upper middle income-countries
n = 28
n (%)
Availability of psychiatric medications
Selective serotonin reuptake inhibitors (SSRIs)a
Available on site 49 (52) 8 (32) 16 (39) 25 (89)
Available only off site 24 (26) 10 (40) 14 (34) 0
Not available 21 (22) 7 (28) 11 (27) 3 (11)
Missing 1 0 1 0
Benzodiazepines
Available on site 77 (81) 19 (76) 32 (76) 26 (93)
Available only off site 7 (7) 4 (16) 3 (7) 0
Not available 11 (12) 2 (8) 7 (17) 2 (7)
Other psychiatric medicationsa
Available on site 67 (71) 18 (72) 25 (60) 24 (89)
Available only off site 16 (17) 6 (24) 9 (21) 1 (4)
Not available 11 (12) 1 (4) 8 (19) 2 (7)
Missing 1 0 0 1
a
Percentages are computed using the number of sites with a non-missing value.
Table 3. Combined availability of screening and on-site management of mental health and substance use disorders at HIV care and
treatment sites within the IeDEA consortium, by mental health or substance use disorder in 2017
Depression
n = 92
n (%)
PTSD
n = 88
n (%)
Substance use disorders
n = 92
n (%)
Other mental health disorders
n = 91
n (%)
Screening and on-site management available 39 (42) 12 (14) 24 (26) 17 (19)
Only screening available 13 (14) 6 (7) 28 (30) 11 (12)
Only on-site management available 25 (27) 33 (38) 14 (15) 26 (29)
Neither screening nor on-site management available 15 (16) 37 (42) 26 (28) 37 (41)
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least commonly reported by health centres. On-site manage-
ment of all MSDs assessed was most commonly reported by
HIV sites that treated adults only and least commonly
reported by HIV sites that treated both adults and children/
adolescents. On-site management of depression and PTSD
were reported significantly more often in urban settings com-
pared to rural settings. On-site management of PTSD, SUDs
and other mental health disorders was reported significantly
more often at public/government-supported facilities as com-
pared to private facilities.
4 | DISCUSSION
We surveyed 95 HIV treatment sites across 29 LMICs to
assess practices for MSD screening and management. Our
analyses suggest that gaps in screening for MSDs in HIV sites
exist, especially in paediatric clinics and in screening for PTSD
in urban settings and middle-income countries. Gaps in man-
agement of MSDs were most commonly reported in rural
settings, paediatric clinics, health centres, private sector facili-
ties and in lower middle-income countries.
These findings highlight the need for additional attention
to the mental health needs of children and adolescents liv-
ing with HIV and integration of mental health services into
paediatric HIV treatment programmes. While data on the
prevalence of MSDs among children and adolescents living
with HIV in LMICs are limited, research indicates that chil-
dren and adolescents living with HIV experience increased
risk of MSDs compared to non-infected peers [23,24]. Simi-
lar to adults, MSDs among children and adolescents are
associated with suboptimal HIV treatment outcomes [25-
27]. Additional research is needed on how to effectively
integrate MSD services into paediatric HIV treatment pro-
grammes in LMICs.
Findings also illustrated disparities in access to MSD treat-
ment between urban and rural communities. Implementation
research is needed to better understand how to integrate evi-
dence-based MSDs services into already overburdened health
systems in LMICs, including in rural settings where on-site
Table 4. Site-level characteristics and availability of screening and on-site management of mental health and substance use
disorders at 95 HIV treatment sites within the IeDEA consortium, by mental health or substance use disorder in 2017a
Characteristic
Total
Screening On-site management
Depression
n (%)
PTSD
n (%)
Substance
use
disorders
n (%)
Other mental
health
disorders
n (%)
Depression
n (%)
PTSD
n (%)
Substance
use
disorders
n (%)
Other mental
health disorders
n(%)
Setting
Urban/mostly urban 76 43 (57) 11 (14) 40 (53) 19 (25) 58 (78) 41 (58) 32 (43) 38 (51)
Rural/mostly rural 19 11 (58) 7 (37) 12 (63) 9 (47) 6 (33) 4 (24) 6 (33) 5 (29)
Level of care
Regional, provincial, or
university hospital
53 27 (51) 5 (9) 28 (53) 14 (26) 42 (81) 32 (65) 26 (50) 34 (68)
District hospital 10 7 (70) 6 (60) 8 (80) 6 (60) 6 (60) 5 (50) 6 (60) 5 (50)
Health centre 32 20 (63) 7 (22) 16 (50) 8 (25) 16 (53) 8 (28) 6 (20) 4 (13)
Patients treated at HIV programme
Adults only 17 11 (65) 1 (6) 10 (59) 2 (12) 15 (94) 12 (80) 12 (75) 13 (81)
Children/adolescents
only
17 5 (29) 3 (18) 3 (18) 4 (24) 13 (77) 10 (59) 7 (41) 9 (53)
Adults and children/
adolescents
61 38 (62) 14 (23) 39 (64) 22 (36) 36 (61) 23 (41) 19 (32) 21 (36)
Sector
Public 84 49 (58) 18 (21) 46 (55) 25 (30) 61 (74) 44 (56) 37 (46) 43 (53)
Private 11 5 (45) 0 6 (55) 3 (27) 3 (30) 1 (11) 1 (9) 0
IeDEA region
Asia-Pacific 28 12 (43) 3 (11) 11 (39) 8 (29) 21 (75) 19 (68) 16 (57) 18 (64)
Caribbean, Central and
South America
8 5 (63) 0 5 (63) 0 7 (88) 4 (57) 4 (57) 4 (50)
Central Africa 10 7 (70) 5 (50) 5 (50) 4 (40) 8 (89) 5 (56) 2 (20) 5 (50)
East Africa 21 10 (48) 4 (19) 12 (57) 9 (43) 8 (42) 6 (32) 8 (41) 7 (37)
Southern Africa 21 14 (67) 5 (24) 16 (76) 5 (24) 14 (67) 7 (37) 5 (24) 5 (26)
West Africa 7 6 (86) 1 (14) 3 (43) 2 (29) 6 (86) 4 (67) 3 (43) 4 (57)
a
Differences that were significant at p < 0.05 level of significance are highlighted in bold. Percentages are computed using the number of sites with
a non-missing value.
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management of MSDs appears to be less available. Additional
in-depth survey data are needed from rural, peripheral sites
to better prioritize MSD integration needs in these settings,
particularly as the majority of sites in the current analysis
were in urban settings.
A substantial minority of sites reported on-site manage-
ment of, but not screening for, depression, PTSD, or other
mental health disorders. Screening in the absence of on-site
management of MSDs was also prevalent, particularly for
SUDs. Most sites reported that they did not screen for
PTSD or other mental health disorders. A substantial minor-
ity also reported not screening for depression or SUDs.
Among sites that reported MSD screening, most reported
screening symptomatic patients. Limited integration of
routine MSDs screening and management may be due to
limited resources or staff members training or capacity and
may be influenced by health system governance and sup-
port for comprehensive care delivery models [28,29]. Such
practices may also reflect concern that routine screening
could overwhelm fragile, underfunded health systems. It is
possible that some clinics may not fully appreciate the level
of unmet need for MSD care among their patient popula-
tion. On-site MSD management in the absence of screening
may occur in health facilities that provide separate MSD
and HIV care, but in which MSD screening has not been
integrated into HIV care or in clinics whose capacity for on-
site MSD management remains limited, reflecting concerns
that screening could overwhelm MSD management capacity.
A lack of MSDs screening and management in many clinics
highlights a current shortcoming of HIV service delivery.
Such situations undermine the potential for success in
achieving UNAIDS 90-90-90 targets [30].
A lack of written guidelines for screening and management
of MSDs was also common among sites assessed. Implementa-
tion of evidence-based guidelines for MSD screening and man-
agement should be prioritized. Almost half of sites reported
not having SSRIs available on site. Psychiatric medications
offer a critical treatment option for individuals with MSDs.
Strategies to increase access to psychiatric medications in HIV
settings, prescribed and managed by trained professionals,
should be explored.
Future research should examine potentially modifiable mul-
ti-level barriers and facilitators, including structural, social and
economic barriers and facilitators to integrating MSD inter-
ventions into HIV care. Greater understanding is needed as to
why some HIV care settings report having integrating MSD
screening or treatments while others have not.
As access to ART and life expectancy of PLWHA increase,
the burden and impact of NCDs among PLWHA, including
MSDs, has gained increased attention [12]. Using existing HIV
care platforms in LMIC to integrate NCD care into HIV and
primary care will be critical to meet NCD-related needs of
PLWHA.
The mhGAP provides guidance for how to integrate MSD
care into primary care settings [14]. Research is needed to
better understand how mhGAP recommendations can be most
effectively implemented into HIV care settings in LMICs.
Future research should examine access to and quality of
MSDs services provided at HIV treatment programmes and
the extent to which such services are evidence-based and
associated with improved MSD and HIV care outcomes.
Research has demonstrated the effectiveness of collaborative
care models to integrate MSD treatment into primary care
[31,32]. While limited, existing research indicates that integrat-
ing MSD care into HIV care in LMICs has the potential to
improve mental health and HIV treatment outcomes [33,34].
Additional research on the effectiveness of integrating MSD
and HIV care is warranted.
This study has limitations worth noting. IeDEA-participating
HIV treatment sites were selected using a stratified random
sampling strategy. While they may be representative of IeDEA,
participating sites may not be representative of all sites or
HIV treatment programmes in a particular country or region.
This analysis relied on reports from health facility staff mem-
bers regarding screening and management of MSDs at partici-
pating clinics. Service access, delivery and quality were not
independently verified by direct observation or review of
medical records and may be over- or under-represented. This
study did not assess specific approaches to MSD screening or
management. Wide variability likely exists in the quality and
procedures related to MSD screening and management in
HIV clinics. Future research should assess how MSD screen-
ing is conducted, including the use of validated MSD screening
tools, how MSD management is conducted in response to pos-
itive MSD screens and the quality of such procedures.
Our study provides initial data on the extent to which
screening and management of MSDs has been integrated into
HIV treatment programmes in LMICs. Our findings can inform
the design of prospective, cohort studies to improve screening
and management of MSDs among PLWHA. Future studies
should advance understanding of multi-level barriers to suc-
cessful integration of MSDs into HIV care in LMICs and iden-
tification of optimal implementation strategies to scale and
sustain integrated MSD and HIV care.
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